Volrick Morrison, DO
Internal Medicine · North Miami Beach, FLNPI 1669611711
Payments from drug & device makers
Across 286 payments — averaging $8394.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1.2M
- Vertex$771K
- Novartis$246K
- Teva Pharmaceuticals USA, Inc.$145K
- Lumos Diagnostics, Inc.$38K
- Sun Pharmaceutical Industries Inc.$15K
- plus $30K from 30 others
Across 2 payments — averaging $40,904 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$82K
What the payments were for
- Food & beverage$4,847100%
- Gifts$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 7 | $1,155,498 |
| Vertex | 3 | $770,883 |
| Novartis | 4 | $246,346 |
| Teva Pharmaceuticals USA, Inc. | 11 | $144,500 |
| Lumos Diagnostics, Inc. | 1 | $38,400 |
| Sun Pharmaceutical Industries Inc. | 1 | $15,250 |
| Hoffmann-la Roche Limited | 2 | $11,500 |
| Chiesi USA, Inc. | 3 | $8,135 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $5,500 |
| Lilly USA, LLC | 73 | $1,087 |
| Novo Nordisk | 50 | $1,066 |
| AstraZeneca | 25 | $498 |
| Boehringer Ingelheim | 18 | $411 |
| Exact Sciences | 20 | $370 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $257 |
| Johnson & Johnson | 11 | $202 |
| Shield Therapeutics Inc | 6 | $189 |
| AbbVie(2 entities) | 10 | $177 |
| Idorsia Pharmaceuticals US Inc | 4 | $96 |
| GSK | 4 | $86 |
| Abbott | 2 | $53 |
| Pfizer | 2 | $47 |
| Amgen(2 entities) | 2 | $38 |
| Pharming Healthcare, Inc. | 1 | $28 |
| CSL Behring | 1 | $27 |
| Astellas Pharma US Inc | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Mayne Pharma Commercial LLC | 1 | $22 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Gilead | 1 | $17 |
| Ascend Therapeutics US, LLC | 1 | $16 |
| Averitas Pharma Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$2,400,857 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $51,059 |
| MounjaroTirzepatide | 17 | $32,339 |
| JardianceEmpagliflozin | 20 | $21,821 |
| FarxigaDapagliflozin Propanediol | 16 | $17,460 |
| LinzessLinaclotide | 12 | $10,799 |
| Rosuvastatin Calcium | 71 | $2,046 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $1,135 |
| Ezetimibe | 14 | $745 |
| Duloxetine Hcl | 22 | $716 |
| Gabapentin | 46 | $692 |
| Nifedipine ErNifedipine | 32 | $687 |
| Telmisartan | 20 | $672 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 23 | $671 |
| Atorvastatin Calcium | 79 | $609 |
| Valsartan | 12 | $556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,066 | $51,05946 claims |
| Lilly USA, LLCMounjaro | $1,087 | $32,33917 claims |
| Boehringer IngelheimJardiance | $411 | $21,82120 claims |
| AstraZenecaFarxiga | $498 | $17,46016 claims |
| AbbVieLinzess | $177 | $10,79912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in North Miami Beach
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.